BioLineRx Ltd.
BLRX
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarciā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.82
Price+4.45%
$0.12
1Y
Price
Market Cap
$12.271m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-117.8%
Net Profit Margin-3.6%
Free Cash Flow Margin-
EBITDA Margin-117.8%
Net Profit Margin-3.6%
Free Cash Flow MarginRevenue
$1.403m
-40.4%
1y CAGR+154.2%
3y CAGR+115.6%
5y CAGREarnings
-$8.892m
+15.2%
1y CAGR-14.3%
3y CAGR-8.8%
5y CAGREPS
-$2.12
-1941.7%
1y CAGR-650.1%
3y CAGR-482.2%
5y CAGRBook Value
$20.835m
$38.797m
Assets$17.962m
Liabilities$9.070m
DebtDebt to Assets
23.4%
2.4x
Debt to EBITDAFree Cash Flow
-$7.823m
+51.7%
1y CAGR-8.8%
3y CAGR-9.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company